STAAR SURGICAL CO
For the period ended Dec 29, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| STAAR SURGICAL COMPANY | ||
| Date: February 27, 2024 | By: | /s/ THOMAS G. FRINZI |
|---|---|---|
| Thomas G. Frinzi | ||
| President, Chief Executive Officer and Chair of the Board | ||
| (principal executive officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ THOMAS G. FRINZI | President, Chief Executive Officer and Chair of the Board, Director | February 27, 2024 |
| Thomas G. Frinzi | (principal executive officer) | |
| /s/ PATRICK F. WILLIAMS | Vice President, Chief Financial Officer | February 27, 2024 |
| Patrick F. Williams | (principal accounting and financial officer) | |
| /s/ STEPHEN C. FARRELL | Director | February 27, 2024 |
| Stephen C. Farrell | ||
| /s/ AIMEE S. WEISNER | Director | February 27, 2024 |
| Aimee S. Weisner | ||
| /s/ ELIZABETH YEU | Director | February 27, 2024 |
| Elizabeth Yeu | ||
| /s/ K. PEONY YU | Director | February 27, 2024 |
| K. Peony Yu | ||
| /s/ LILIAN ZHOU | Director | February 27, 2024 |
| Lilian Zhou | ||
CONSOLIDATED FINANCIAL STATEMENTS
TABLE OF CONTENTS
| Report of Independent Registered Public Accounting Firm (BDO USA, P.C.; Los Angeles, California; PCAOB ID#243) | F-2 |
|---|---|
| Consolidated Balance Sheets at December 29, 2023 and December 30, 2022 | F-4 |
| Consolidated Statements of Income for the years ended December 29, 2023, December 30, 2022 and December 31, 2021 | F-5 |
| Consolidated Statements of Comprehensive Income for the years ended December 29, 2023, December 30, 2022 and December 31, 2021 | F-6 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 29, 2023, December 30, 2022 and December 31, 2021 | F-7 |
| Consolidated Statements of Cash Flows for the years ended December 29, 2023, December 30, 2022 and December 31, 2021 | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
| Schedule II Valuation and Qualifying Accounts and Reserves | F-39 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.